SML1119
LDN-214117
≥98% (HPLC)
别名:
1-(4-(6-Methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C25H29N3O3
化学文摘社编号:
分子量:
419.52
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
SMILES string
CC(C(C1=CC(OC)=C(OC)C(OC)=C1)=C2)=NC=C2C(C=C3)=CC=C3N4CCNCC4
InChI
1S/C25H29N3O3/c1-17-22(19-14-23(29-2)25(31-4)24(15-19)30-3)13-20(16-27-17)18-5-7-21(8-6-18)28-11-9-26-10-12-28/h5-8,13-16,26H,9-12H2,1-4H3
InChI key
BHUXVRVMMYAXKN-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
2-8°C
Quality Level
Application
LDN-214117 has been used in structure-activity relationship (SAR) study to evaluate its potency on selective inhibition of activin receptor-like kinase-2 (ALK2) through the kinome-wide selectivity of (LDN-214117) via enzymatic kinase profiling.
Biochem/physiol Actions
LDN-214117 is a selective inhibitor of the bone morphogenetic protein (BMP) type I receptor kinases with high selectivity for BMP versus TGF-β signaling, and low cytotoxicity. LDN-214117 inhibited ALK2 most, with a biochemical IC50 of 24 nM, followed by TNIK, RIPK2, and ABL1. LDN-214117 has a cell-based IC50 for BMP6 of approximately 100 nM and 164-fold selectivity for BMP6 versus TGF-β1. Fibrodysplasia ossificans progressiva (FOP) is a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2. LDN-214117 had nearly identical binding affinity for wild-type ALK2 and each of the FOP-causing mutants tested.
LDN-214117 is a selective inhibitor of the bone morphogenetic protein (BMP) type I receptor kinases.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Agustin H Mohedas et al.
Journal of medicinal chemistry, 57(19), 7900-7915 (2014-08-08)
There are currently no effective therapies for fibrodysplasia ossificans progressiva (FOP), a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2. Recently, a subset of these same mutations of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持